A Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of LYC-30937-EC in Subjects With Moderate Chronic Plaque-Type Psoriasis
Phase of Trial: Phase II
Latest Information Update: 28 Jul 2017
At a glance
- Drugs LYC 30937 (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms UPRISE
- Sponsors Lycera
- 25 Jul 2017 Status changed from recruiting to completed.
- 27 Mar 2017 Planned End Date changed from 1 Jul 2017 to 1 Jun 2017.
- 23 Feb 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Jun 2017.